HIV prevention transformed: The new prevention research agenda

The Lancet

Volumn 378, Issue 9787, 2011, Pages 269-278

  Padian, Nancy S ^a,b   McCoy, Sandra I ^a   Karim, Salim S Abdool ^f,g   Hasen, Nina ^b   Kim, Julia ^h   Bartos, Michael ⁱ   Katabira, Elly ^j   Bertozzi, Stefano M ^c,d,e   Schwartländer, Bernhard ⁱ   Cohen, Myron S ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b U S DEPARTMENT OF STATE   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g University of KwaZulu Natal ^*  (United States)

^h BDP   (United States)

ⁱ UNAIDS   (Switzerland)

^j MAKERERE UNIVERSITY   (Uganda)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BEHAVIOR THERAPY; CANARYPOX VIRUS; CD4 LYMPHOCYTE COUNT; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CIRCUMCISION; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HERPES SIMPLEX VIRUS 2; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGICAL MONITORING; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; KIDNEY DYSFUNCTION; LOWEST INCOME GROUP; MATHEMATICAL MODEL; MOTHER CHILD RELATION; NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; TRICHOMONAS VAGINALIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ZIMBABWE;

EID: 79960352907     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60877-5     Document Type: Review

References (137)

1. P Piot, M Bartos, H Larson, D Zewdie, P Mane Coming to terms with complexity: a call to action for HIV prevention Lancet 372 2008 845 859
2. NS Padian, A Buvé, J Balkus, D Serwadda, W Cates Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward Lancet 372 2008 585 599
3. GR Gupta, JO Parkhurst, JA Ogden, P Aggleton, A Mahal Structural approaches to HIV prevention Lancet 372 2008 764 775
4. TJ Coates, L Richter, C Caceres Behavioural strategies to reduce HIV transmission: how to make them work better Lancet 372 2008 669 684
5. NS Padian, SI McCoy, JE Balkus, JN Wasserheit Weighing the gold in the gold standard: challenges in HIV prevention research AIDS 24 2010 621 635
6. EC Green, DT Halperin, V Nantulya, JA Hogle Uganda's HIV prevention success: the role of sexual behavior change and the national response AIDS Behav 10 2006 335 346 (Pubitemid 44174960)
7. DT Halperin, O Mugurungi, TB Hallett et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med 8 2011 e1000414
8. S Gregson, E Gonese, TB Hallett et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review Int J Epidemiol 39 2010 1311 1323
9. J Cohen Anti-HIV pill protects against AIDS. ScienceNOW http://news.sciencemag.org/sciencenow/2010/11/hiv-prevent-treat.html Nov 23, 2010 (accessed March 1, 2011).
10. HIV Vaccines and Microbicides Resource Tracking Working Group Advancing the science in a time of fiscal constraint: funding for HIV prevention technologies in 2009 http://www.iavi.org/Lists/IAVIPublications/attachments/ 1afc3074-4e79-4eb1-a6e1-e2a4c155e7c3/HVMRTWG-ADVANCING-THE-SCIENCE-2010-ENG.pdf July, 2010 (accessed March 1, 2011).
11. MJ McElrath, BF Haynes Induction of immunity to human immunodeficiency virus type-1 by vaccination Immunity 33 2010 542 554
12. NL Letvin Virology. Moving forward in HIV vaccine development Science 326 2009 1196 1198
13. SP Buchbinder, DV Mehrotra, A Duerr for the Step Study Protocol Team Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet 372 2008 1881 1893
14. M Rolland, S Tovanabutra, AC deCamp et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial Nat Med 17 2011 366 371
15. S Rerks-Ngarm, P Pitisuttithum, S Nitayaphan for the MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand N Engl J Med 361 2009 2209 2220
16. G Ferrari, J Pollara, D Kozink et al. A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent ADCC activity and defines a common ADCC epitope in human HIV-1 serum J Virol 2011 10.1128/JVI.00171-11 published online May 4.
17. MS Cohen, GM Shaw, AJ McMichael, BF Haynes Acute HIV-1 infection N Engl J Med 364 2011 1943 1954
18. DD Richman, DM Margolis, M Delaney, WC Greene, D Hazuda, RJ Pomeranta The challenge of finding a cure for HIV infection Science 323 2009 1304 1307
19. G Hütter, D Nowak, M Mossner et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 2009 692 698
20. P Cannon, C June Chemokine receptor 5 knockout strategies Curr Opin HIV AIDS 6 2011 74 79
21. N Chomont, M El-Far, P Ancuta et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation Nat Med 15 2009 893 900
22. DM Margolis Eradication therapies for HIV infection: time to begin again AIDS Res Hum Retroviruses 27 2011 347 353
23. JD Siliciano, RF Siliciano Biomarkers of HIV replication Curr Opin HIV AIDS 5 2010 491 497
24. N Goonetilleke, MK Liu, JF Salazar-Gonzalez et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection J Exp Med 206 2009 1253 1272
25. F Pereyra, MM Addo, DE Kaufmann et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy J Infect Dis 197 2008 563 571 (Pubitemid 351321534)
26. D Trono, C Van Lint, C Rouzioux et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals Science 329 2010 174 180
27. Department of Health and Human Services Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-D) (UM1) http://grants.nih.gov/grants/ guide/rfa-files/RFA-AI-11-002.html March 29, 2011 (accessed May 10, 2011).
28. Ba-L J Virol 84 2010 1302 1313
29. L Stamatatos, L Morris, DR Burton, JR Mascola Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15 2009 866 870
30. GD Tomaras, NL Yates, P Liu et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia J Virol 82 2008 12449 12463
31. JB Angel, JP Routy, C Tremblay et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune AIDS 25 2011 731 739
32. ClinicalTrials.gov. Therapeutic intensification plus immunomodulation to decrease the HIV-1 viral reservoir (EraMune02). June 13, 2011. http://clinicaltrials.gov/ct2/show/NCT00976404 (accessed April 2, 2011).
33. Department of Health and Human Services Martin Delaney Collaboratory: towards an HIV-1 cure (U19) http://grants.nih.gov/grants/guide/rfa-files/RFA-AI- 10-009.html Sept 16, 2010 (accessed May 10, 2011).
34. MS Cohen, C Gay, AD Kashuba, S Blower, L Paxton Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1 Ann Intern Med 146 2007 591 601 (Pubitemid 351650540)
35. Q Abdool Karim, SS Abdool Karim, JA Frohlich for the CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
36. Microbicide Trials Network MTN-003 http://www.mtnstopshiv.org/node/70 2011 (accessed March 26, 2011).
37. AVAC: Global Advocacy for HIV Prevention Ongoing pre-exposure prophylaxis (PrEP) trials http://www.avac.org/ht/a/GetDocumentAction/i/3113 February, 2011 (accessed March 26, 2011).
38. UM Parikh, C Dobard, S Sharma et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine J Virol 83 2009 10358 10365
39. RM Grant, JR Lama, PL Anderson for the iPrEx Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2010 2587 2599
40. Family Health International FHI Statement on the FEM-PrEP HIV Prevention Study http://www.fhi.org/en/AboutFHI/Media/Releases/FEM-PrEP-statement041811.htm April 18, 2011 (accessed April 22, 2011).
41. K Patterson, H Prince, E Kraft et al. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP). XVIII International AIDS Conference; Vienna, Austria http://pag.aids2010.org/Session. aspx?s=6825 July 18-23, 2010 (accessed March 1, 2011).
42. SS Abdool Karim, ADM Kashuba, L Werner, Q Abdool Karim Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women Lancet 378 2011 279 281
43. KH Mayer, KK Venkatesh Antiretroviral therapy as HIV prevention: status and prospects Am J Public Health 100 2010 1867 1876
44. TC Quinn, MJ Wawer, N Sewankambo et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group N Engl J Med 342 2000 921 929 (Pubitemid 30177052)
45. K Smith, KA Powers, AD Kashuba, MS Cohen HIV-1 treatment as prevention: the good, the bad, and the challenges Curr Opin HIV AIDS 6 2011 315 325
46. HIV Prevention Trials Network HPTN 052: a randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples http://www.hptn.org/research-studies/hptn052.asp 2011 (accessed May 10, 2011).
47. National Institute of Allergy and Infectious Diseases Treating HIV-infected people with antiretrovirals protects partners from infection http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx May 12, 2011 (accessed May 12, 2011).
48. UL Abbas Uptake of biomedical interventions for prevention of sexually transmitted HIV Curr Opin HIV AIDS 6 2011 114 118
49. RM Granich, CF Gilks, C Dye, KM De Cock, BG Williams Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model Lancet 373 2009 48 57
50. C Pretorius, J Stover, L Bollinger, N Bacaër, B Williams Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa PLoS One 5 2010 e13646
51. WHO Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf November, 2009 (accessed March 1, 2011).
52. UNAIDS Global report: report on the global AIDS epidemic http://www.unaids.org/globalreport/documents/20101123-GlobalReport-full-en.pdf 2010 (accessed March 3, 2011).
53. S Rosen, M Fox, B Larson From HIV testing to treatment initiation: the missing link. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011 http://retroconference.org/2011/Abstracts/ 42657.htm (accessed April 22, 2011).
54. V Novitsky, R Wang, H Bussmann et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission PLoS One 5 2010 e10148
55. BM Branson The future of HIV testing J Acquir Immune Defic Syndr 55 suppl 2 2010 S102 S105
56. EM Gardner, MP McLees, JF Steiner, C del Rio, WJ Burman The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection Clin Infect Dis 52 2011 793 800
57. R Zachariah, N Ford, M Philips et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa Trans R Soc Trop Med Hyg 103 2009 549 558
58. WHO Task Shifting: global recommendations and guidelines http://www.who.int/healthsystems/TTR-TaskShifting.pdf 2008 (accessed March 3, 2011).
59. JE Haberer, J Kahane, I Kigozi et al. Real-time adherence monitoring for HIV antiretroviral therapy AIDS Behav 14 2010 1340 1346
60. LC Rohan, AB Sassi Vaginal drug delivery systems for HIV prevention AAPS J 11 2009 78 87
61. Dobard C, Sharma S, Parikh U, et al. High Protection against vaginal infection in macaques by PEP with gel containing RA. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011.
62. SD Pinkerton, DR Holtgrave, CL Galletly Infections prevented by increasing HIV serostatus awareness in the United States, 2001 to 2004 J Acquir Immune Defic Syndr 47 2008 354 357 (Pubitemid 351619423)
63. JA Denison, KR O'Reilly, GP Schmid, CE Kennedy, MD Sweat HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005 AIDS Behav 12 2008 363 373
64. M Sweat, S Morin, D Celentano for the Project Accept study team Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study Lancet Infect Dis 2011 10.1016/S1473-3099(11)70060-3 published online May 3.
65. WHO/UNAIDS Guidance on provider-initiated HIV testing and counselling in health facilities http://www.who.int/hiv/pub/guidelines/9789241595568-en.pdf 2007 (accessed March 4, 2011).
66. DJ Koo, EM Begier, MH Henn, KA Sepkowitz, SE Kellerman HIV counseling and testing: less targeting, more testing Am J Public Health 96 2006 962 964 (Pubitemid 43825259)
67. WHO/UNAIDS/UNICEF Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008 http://www.who.int/hiv/ pub/towards-universal-access-report-2008.pdf 2008 (accessed March 8, 2011).
68. SD Weiser, M Heisler, K Leiter et al. Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns PLoS Med 3 2006 e261
69. Walensky RP, Wood R, Fofana MO, et al, for the Cost-Effectiveness of Preventing AIDS Complications-International Investigators. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 56: 26-35.
70. MM Kitahata, SJ Gange, AG Abraham for the NA-ACCORD Investigators Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med 360 2009 1815 1826
71. Measure Demographic and Health Surveys HIV/AIDS survey indicators database http://www.measuredhs.com/hivdata 2011 (accessed March 3, 2011).
72. WHO and Population Council HIV testing, treatment, and prevention: generic tools for operational research http://www.who.int/hiv/pub/operational/ or-generic-tools.pdf 2009 (accessed March 3, 2011).
73. SD Weiser, M Heisler, K Leiter et al. Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns PLoS Med 3 2006 e261
74. A Medley, C Garcia-Moreno, S McGill, S Maman Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes Bull World Health Organ 82 2004 299 307 (Pubitemid 38568468)
75. MH Bateganya, OA Abdulwadud, SM Kiene Home-based HIV voluntary counseling and testing in developing countries Cochrane Database Syst Rev 17 2007 CD006493.
76. R Thornton The demand for and impact of learning HIV status Am Econ Rev 98 2008 1829 1863
77. WHO/UNICEF, The Interagency Task Team on Prevention of HIV Infection in Pregnant Women, Mothers and their Children Guidance on global scale-up of the prevention of mother-to-child transmission of HIV: towards universal access for women, infants and young children and eliminating HIV and AIDS among children http://www.unicef.org/aids/files/PMTCT-enWEBNov26.pdf 2007 (accessed March 3, 2011).
78. M Mahy, J Stover, K Kiragu et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs Sex Transm Infect 86 suppl 2 2010 ii48 ii55
79. WHO Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach - 2010 version http://whqlibdoc.who.int/publications/2010/9789241599818-eng.pdf 2010 (accessed March 4, 2011).
80. E Paintsil, WA Andiman Update on successes and challenges regarding mother-to-child transmission of HIV Curr Opin Pediatr 21 2009 94 101
81. WHO Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants http://www.who.int/hiv/pub/mtct/rapid- advice-mtct.pdf 2009 (accessed March 4, 2011).
82. HW Reynolds, B Janowitz, R Wilcher, W Cates Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries Sex Transm Infect 84 suppl 2 2008 ii49 ii53
83. US Agency for International Development. Quality Improvement Approaches and Results for Prevention of Mother-to-Child HIV Transmission (PMTCT). 2011.
84. WHO Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: guidelines on care, treatment, and support for women living with HIV/AIDS and their children in resource-constrained settings http://www.who.int/hiv/pub/mtct/en/arvdrugswomenguidelinesfinal.pdf 2004 (accessed March 5, 2011).
85. WHO/UNAIDS/UNICEF Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009 http://www.who.int/hiv/ pub/tuapr-2009-en.pdf 2009 (accessed March 4, 2011).
86. L Tsague, FO Tsiouris, RJ Carter et al. Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens BMC Public Health 10 2010 753
87. SD Mehta, RH Gray, B Auvert et al. Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials AIDS 23 2009 1557 1564
88. E Mills, C Cooper, A Anema, G Guyatt Male circumcision for the prevention of heterosexually acquired HIV infection: a meta analysis of randomized trials involving 11 050 men HIV Med 9 2008 332 335 (Pubitemid 352015640)
89. N Siegrfried, M Muller, JJ Deeks, J Volmink Male circumcision for prevention of heterosexual acquisition of HIV in men Cochrane Database Syst Rev 2 2009 CD003362.
90. MJ Wawer, F Makumbi, G Kigozi et al. Randomized trial of male circumcision in HIV-infected men: effects on HIV transmission to female partners, Rakai, Uganda Lancet 374 2009 229 237
91. RH Gray, N Kiwanuka, TC Quinn et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team AIDS 14 2000 2371 2381
92. JM Baeten, D Donnell, SH Kapiga for the Partners in Prevention HSV/HIV Transmission Study Team Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples AIDS 24 2010 737 744
93. TB Hallett, RA Alsallaq, JM Baeten et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions Sex Transm Infect 87 2010 88 93
94. AA Tobian, D Serwadda, TC Quinn et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis N Engl J Med 360 2009 1298 1309
95. B Auvert, J Sobngwi-Tambekou, E Cutler et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa J Infect Dis 199 2009 14 19
96. MJ Wawer, AA Tobian, G Kigozi et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda Lancet 377 2011 209 218
97. J Sobngwi-Tambekou, D Taljaard, M Nieuwoudt, P Lissouba, A Puren, B Auvert Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention Sex Transm Infect 85 2009 116 120
98. SD Mehta, S Moses, K Agot et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya J Infect Dis 200 2009 370 378
99. Government of Kenya, Ministry of Public Health and Sanitation, National AIDS and STI Control Programme Progress report on Kenya's voluntary medical male circumcision programme: 2008-09 summary http://www.malecircumcision.org/ documents/VMMCP-Report.pdf July, 2010 (accessed March 27, 2011).
100. Curran K, Mahler H, Kileo B, et al. An efficient campaign for rapid scale-up of safe male circumcision services in a high HIV prevalence region, Tanzania. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011.
101. S Moses, JE Bradley, NJ Nagelkerke et al. Geographical patterns of male circumcision practices in Africa: association with HIV seroprevalence Int J Epidemiol 19 1990 693 697 (Pubitemid 20331819)
102. S Moses, FA Plummer, JE Bradley, JO Ndinya-Achola, NJ Nagelkerke, AR Ronald The association between lack of male circumcision and risk for HIV infection: a review of the epidemiological data Sex Transm Dis 21 1994 201 210 (Pubitemid 24310169)
103. Bitega JP, Ngeruka ML, Hategekimana T, Asiimwe A, Bingawaho A. Safety and efficacy study of the PrePex system for male circumcision. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011.
104. MA Barone, F Ndede, PS Li et al. The Shang Ring device for adult male circumcision: a proof of concept study in Kenya J Acquir Immune Defic Syndr 2011 10.1097/QAI.0b013e3182158967 published online May 1.
105. R Kagumire Ugandan effort to constrain HIV spread hampered by systemic and cultural obstacles to male circumcision CMAJ 179 2008 1119 1120
106. R Tenthani Malawi rules out circumcision for Aids prevention http://mg.co.za/article/2010-09-16-malawi-rules-out-circumcision-for-aids- prevention Sept 16, 2010 (accessed March 27, 2011).
107. JM Bengo, K Chalulu, J Chinkhumba et al. Situation analysis of male circumcision in Malawi April, 2010 College of Medicine Lilongwe, Malawi http://www.nurhi.org/toolkits/malawi/situation-analysis-male-circumcision- malawi (accessed March 29, 2011).
108. PM Pronyk, JR Hargreaves, JC Kim et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial Lancet 368 2006 1973 1983 (Pubitemid 44821362)
109. PM Pronyk, JC Kim, T Abramsky et al. A combined microfinance and training intervention can reduce HIV risk behaviour in young female participants AIDS 22 2008 1659 1665
110. R Jewkes, M Nduna, J Levin et al. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial BMJ 337 2008 a506
111. Baird S, McIntosh C, Özler B. Schooling, income, and HIV risk: experimental evidence from a cash transfer program. XVIII International AIDS Conference; Vienna, Austria; July 18-23, 2010.
112. S Baird, E Chirwa, C McIntosh, B Özler The short-term impacts of a schooling conditional cash transfer program on the sexual behavior of young women Health Econ 19 suppl 2010 55 68
113. The World Bank Malawi and Tanzania research shows promise in preventing HIV and sexually-transmitted infections http://web.worldbank.org/WBSITE/ EXTERNAL/NEWS/0,contentMDK:22649337∼pagePK:34370∼piPK: 34424∼theSitePK:4607,00.html July 18, 2010
114. HP Kohler, R Thornton Conditional cash transfers and HIV/AIDS prevention: unconditonally promising? http://www-personal.umich.edu/∼rebeccal/ RebeccaLThornton/Home-files/KohlerThornton.CCTHIV.pdf Sept 29, 2010 (accessed March 28, 2011).
115. J Kim, P Pronyk, T Barnett, C Watts Exploring the role of economic empowerment in HIV prevention AIDS 22 suppl 4 2008 S57 S71
116. M Shahmanesh, V Patel, D Mabey, F Cowan Effectiveness of interventions for the prevention of HIV and other sexually transmitted infections in female sex workers in resource poor setting: a systematic review Trop Med Int Health 13 2008 659 679 (Pubitemid 351561603)
117. L Degenhardt, B Mathers, P Vickerman, T Rhodes, C Latkin, M Hickman Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed Lancet 376 2010 285 301
118. SA Strathdee, TB Hallett, N Bobrova et al. HIV and risk environment for injecting drug users: the past, present, and future Lancet 376 2010 268 284
119. Department for International Development HRPC10: tackling the structural drivers of the HIV epidemic http://webarchive.nationalarchives.gov.uk/+/http:// www.dfid.gov.uk/Working-with-DFID/Procurement/Current-contract-opportunities1/ UK-East-Kilbride-HRPC10-Tackling-the-Structural-Drivers-of-the-HIV-Epidemic Jan 25, 2010 (accessed April 2, 2011).
120. J Auerbach Transforming social structures and environments to help in HIV prevention Health Aff 28 2009 1655 1665
121. J Kim, G Ferrari, T Abramsky et al. Assessing the incremental effects of combining economic and health interventions: the IMAGE study in South Africa Bull World Health Organ 87 2009 824 832
122. C Medlin, D de Walque Potential applications of conditional cash transfers for prevention of sexually transmitted infections and HIV in Sub-Saharan Africa http://www-wds.worldbank.org/external/default/ WDSContentServer/IW3P/IB/2008/07/22/000158349-20080722084441/Rendered/PDF/ WPS4673.pdf July, 2008 (accessed March 28, 2011).
123. International Group on Analysis of Trends in HIV Prevalence and Behaviours in Young People in Countries most Affected by HIV Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV Sex Transm Infect 86 suppl 2 2010 ii72 ii83
124. S Gregson, S Adamson, S Papaya et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe PLoS Med 4 2007 e102
125. MN Lurie, S Rosenthal Concurrent partnerships as a driver of the HIV Epidemic in sub-Saharan Africa? The evidence is limited AIDS Behav 14 2010 17 24
126. TL Mah, DT Halperin Concurrent sexual partnerships and the HIV epidemics in Africa: evidence to move forward AIDS Behav 14 2010 11 16
127. Southern African Development Community Expert think tank meeting on HIV prevention in high-prevalence countries in southern Africa: report http://data.unaids.org/pub/report/2006/20060601-sadc-meeting-report-en.pdf May 10-12, 2006 (accessed March 15, 2011).
128. L Letsela, R Weiner Soul City Institute for Health and Development Communication The OneLove Campaign in South Africa: what has been achieved so far? Interim evaluation http://change.comminit.com/en/node/332620 Oct 1, 2009 (accessed March 15, 2011).
129. LM McDaid, GJ Hart Sexual risk behaviour for transmission of HIV in men who have sex with men: recent findings and potential interventions Curr Opin HIV AIDS 5 2010 311 315
130. G Prestage, L Mao, S Kippax et al. Use of viral load to negotiate condom use among gay men in Sydney, Australia AIDS Behav 13 2009 645 651
131. P Vernazza, B Hirschel, E Bernasconi, M Flepp HIV-positive people not suffering any other STD and effective antiretroviral therapy do not transmit HIV through sexual. Bull Swiss Phys http://papamamanbebe.net/a8238-les-personnes- seropositives-ne-souffrant-d-a.html Jan 30, 2008 (in French).
132. J Kimber, N Palmateer, S Hutchinson et al. Harm reduction among injecting drug users - evidence of effectiveness. In: Rhodes T, Hedrich D, eds. Harm Reduction: evidence, impacts and challenges http://www.emcdda.europa.eu/ attachements.cfm/att-101268-EN-emcdda-harm20red-mon-ch5-web.pdf April, 2010 (accessed March 28, 2011).
133. L Peterson, D Taylor, R Roddy et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial PLoS Clin Trials 2 2007 e27
134. B Schwartländer, J Stover, T Hallet for the Investment Framework Study Group Towards an improved investment approach for an effective response to HIV/AIDS Lancet 377 2011 2031 2041
135. AD Oxman, A Bjørndal, F Becerra-Posada et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions Lancet 375 2010 427 431
136. NS Padian, SI McCoy, S Manian, D Wilson, B Schwartländer, S Bertozzi Evaluation of combination HIV prevention programs: essential issues J Acquir Immune Defic Syndr 2011 10.1097/QAI.0b013e318227af37 published online June 18.
137. M Merson, N Padian, TJ Coates for The Lancet HIV Prevention Series Authors Combination HIV prevention Lancet 372 2008 1805 1806